Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Name: Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
Published: 2007
License: Public Domain

Novartis Pharmaceuticals · 2007

ClinicalTrials.gov · Datasets · License: Public Domain · 2007

Open Source ↗

breast-cancer

breast cancer, hematologic neoplasms, auy922, solid tumors, phase i/ii, advanced solid malignancies (phase i), breast cancer ( phase ii ), her2+, er+, hsp90, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Related documents